- R&D
Élancé Therapeutics Joins the Race to Develop Next-Generation Obesity Therapies
China-based Harbour BioMed has recently announced the establishment of a new biotechnology company, Élancé Therapeutics. This initiative is focused on developing bispecific antibodies designed...Roche Comes Out With Novel ‘Sequencing-By-Expansion’ Approach
Roche has proposed a fresh kind of genetic analysis. This process, which the company refers to as sequencing-by-expansion, is a patented technique that involves...Sionna Therapeutics Targets $156 Million in IPO to Advance Cystic Fibrosis Research
Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusetts, is preparing to raise up to $156 million through an initial public offering (IPO) as...Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...
- Clinical
Pfizer and Arvinas disclose mixed breast cancer survival findings for PROTAC degrader
Pfizer and Arvinas reported that their estrogen receptor degrader failed to meet positive results in a major stage of its first phase 3 trial....J&J Halts Phase 3 Depression Program Over Efficacy Concerns
Johnson & Johnson has contributed to the ongoing issues surrounding opioids. Months after Neumora's phase 3 failure, J&J has halted the development of its...Merck KGaA Continues Enpatoran Development Despite Phase 2 SLE Trial Setback
Merck KGaA has faced a challenge in the clinical evaluation of its investigational oral TLR7/8 inhibitor, enpatoran, for systemic lupus erythematosus (SLE). Although the...BioNTech’s Malaria Vaccine Trial Temporarily Suspended by FDA
The U.S. Food and Drug Administration (FDA) has placed a hold on BioNTech’s phase 1/2a clinical trial, temporarily suspending the company’s progress in developing...
- Commercial
Amgen and CytomX remove disguised T-cell engager and axe the asset
The phase 1 T-cell engager developed by Amgen and CytomX Therapeutics was terminated because both organizations evaluated clinical outcomes and their research strategies. The...Teleflex Restructures Amidst €760 Million Biotronik Deal, Paving the Way for Two Independent Businesses
Teleflex has announced plans to restructure its operations by creating two independent businesses, a move driven in part by its recent €760 million ($791...Regeneron Shifts Strategy for Lymphoma Bispecific, Focuses on Follicular Lymphoma
Regeneron has adjusted its regulatory approach for odronextamab, opting to pursue accelerated approval only in relapsed or refractory follicular lymphoma (FL) while dropping plans...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
- R&D
Élancé Therapeutics Joins the Race to Develop Next-Generation Obesity Therapies
China-based Harbour BioMed has recently announced the establishment of a new biotechnology company, Élancé Therapeutics. This initiative is focused on developing bispecific antibodies designed...Roche Comes Out With Novel ‘Sequencing-By-Expansion’ Approach
Roche has proposed a fresh kind of genetic analysis. This process, which the company refers to as sequencing-by-expansion, is a patented technique that involves...Sionna Therapeutics Targets $156 Million in IPO to Advance Cystic Fibrosis Research
Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusetts, is preparing to raise up to $156 million through an initial public offering (IPO) as...Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...
- Clinical
Pfizer and Arvinas disclose mixed breast cancer survival findings for PROTAC degrader
Pfizer and Arvinas reported that their estrogen receptor degrader failed to meet positive results in a major stage of its first phase 3 trial....J&J Halts Phase 3 Depression Program Over Efficacy Concerns
Johnson & Johnson has contributed to the ongoing issues surrounding opioids. Months after Neumora's phase 3 failure, J&J has halted the development of its...Merck KGaA Continues Enpatoran Development Despite Phase 2 SLE Trial Setback
Merck KGaA has faced a challenge in the clinical evaluation of its investigational oral TLR7/8 inhibitor, enpatoran, for systemic lupus erythematosus (SLE). Although the...BioNTech’s Malaria Vaccine Trial Temporarily Suspended by FDA
The U.S. Food and Drug Administration (FDA) has placed a hold on BioNTech’s phase 1/2a clinical trial, temporarily suspending the company’s progress in developing...
- Commercial
Amgen and CytomX remove disguised T-cell engager and axe the asset
The phase 1 T-cell engager developed by Amgen and CytomX Therapeutics was terminated because both organizations evaluated clinical outcomes and their research strategies. The...Teleflex Restructures Amidst €760 Million Biotronik Deal, Paving the Way for Two Independent Businesses
Teleflex has announced plans to restructure its operations by creating two independent businesses, a move driven in part by its recent €760 million ($791...Regeneron Shifts Strategy for Lymphoma Bispecific, Focuses on Follicular Lymphoma
Regeneron has adjusted its regulatory approach for odronextamab, opting to pursue accelerated approval only in relapsed or refractory follicular lymphoma (FL) while dropping plans...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
Editor Picks
Angle Health secures investment worth $58 million for expansion of operations
Angle Health, an employee-focused digital health insurance provider, has raised $58 million...
Revolo Reveals Positive Midphase Data For EoE Candidate
Revolo Biotherapeutics believes that it possesses the data necessary to continue developing...
Third antibody treatment for early COVID infection approved by the FDA
The United States FDA ( Food and Drug Administration) has approved the monoclonal antibody therapy treatment of Vir Biotechnology and GSK ( GlaxoSmithKline) on Wednesday
Must Read
Merck develops $1B Gardasil production plant in North Carolina
The Durham complex of Merck now operates a new $1 billion, massive 225,000-square-foot bulk...
Élancé Therapeutics Joins the Race to Develop Next-Generation Obesity Therapies
China-based Harbour BioMed has recently announced the establishment of a new biotechnology company, Élancé...
Merck Increases Vaccine Production With New $1B Manufacturing Facility in North Carolina
Merck has inaugurated a fresh $1 billion, 225,000-square-foot manufacturing site at its extensive compound...
About Us
Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.
Contact us: reachout(at)lifescivoice.com